ARK Investment Management LLC Has $260.04 Million Stake in Twist Bioscience Co. (NASDAQ:TWST)

ARK Investment Management LLC raised its position in Twist Bioscience Co. (NASDAQ:TWST) by 4.4% during the fourth quarter, Holdings Channel reports. The firm owned 5,595,865 shares of the company’s stock after purchasing an additional 237,772 shares during the period. Twist Bioscience comprises 2.2% of ARK Investment Management LLC’s portfolio, making the stock its 13th largest holding. ARK Investment Management LLC owned 0.09% of Twist Bioscience worth $260,040,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TWST. Signaturefd LLC lifted its position in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the period. International Assets Investment Management LLC lifted its position in shares of Twist Bioscience by 4,418.3% in the 3rd quarter. International Assets Investment Management LLC now owns 4,925 shares of the company’s stock worth $223,000 after purchasing an additional 4,816 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Twist Bioscience by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,268 shares of the company’s stock valued at $509,000 after acquiring an additional 4,427 shares in the last quarter. Finally, SteelPeak Wealth LLC bought a new stake in shares of Twist Bioscience in the 3rd quarter valued at $416,000.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $40.81 on Wednesday. The firm has a market capitalization of $2.43 billion, a PE ratio of -12.07 and a beta of 1.87. The firm has a fifty day simple moving average of $47.80 and a two-hundred day simple moving average of $45.70. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience’s quarterly revenue was up 24.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.75) EPS. Analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on TWST shares. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday, February 4th. Wolfe Research started coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, TD Cowen reiterated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and an average price target of $54.40.

Insider Transactions at Twist Bioscience

In other news, CFO Adam Laponis sold 5,886 shares of the company’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the sale, the chief financial officer now owns 110,096 shares in the company, valued at $4,762,752.96. This represents a 5.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Robert Chess sold 2,940 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the sale, the director now owns 18,173 shares of the company’s stock, valued at approximately $965,531.49. The trade was a 13.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,180 shares of company stock worth $1,821,971 in the last quarter. 3.01% of the stock is currently owned by corporate insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.